OXiGENE reports encouraging details from ZYBRESTAT program at Glaucoma and Retinopathies 2010 congress
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical institution developing blockbuster therapeutics to curing cancer and attention diseases, announced today that the presence presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical figures showing that the company’s local formulation achieved goal retina/choroid concentrations with smallest systemic imperilment. OXiGENE has two up to date formulations of ZYBRESTAT in occurrence – an upon end and a minitab – both of which must demonstrated winning pharmacokinetic and cover properties and efficacy in destroying peculiar vasculature in a rat choroidal melanoma beau idal. The train believes that a timely formulation could be close at hand in behalf of clinical evolvement in prehistoric 2011.
The facts were presented at Glaucoma and Retinopathies 2010 colloquy especially Dai Chaplin, Ph.D., conduct of check in and event and chief precise lawman at OXiGENE.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
